Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study

Probiotics Antimicrob Proteins. 2015 Jun;7(2):91-100. doi: 10.1007/s12602-014-9181-3.

Abstract

Reducing the amount of Helicobacter pylori in the stomach by selective bacterial-bacterial cell interaction was sought as an effective and novel method for combating the stomach pathogen. Lactobacillus reuteri DSM17648 was identified as a highly specific binding antagonist to H. pylori among more than 700 wild-type strains of Lactobacillus species. Applying a stringent screening procedure, the strain DSM17648 was identified as selective binder to H. pylori cells under in vivo gastric conditions. The strain DSM17648 co-aggregates the pathogen in vivo and in vitro. The specific co-aggregation occurs between Lact. reuteri DSM17648 and different H. pylori strains and serotypes, as well as H. heilmannii, but not with Campylobacter jejuni or other commensal oral and intestinal bacteria. Lact. reuteri DSM17648 was shown in a proof-of-concept single-blinded, randomized, placebo-controlled pilot study to significantly reduce the load of H. pylori in healthy yet infected adults. Reducing the amount of H. pylori in the stomach by selective bacterial-bacterial cell interaction might be an effective and novel method for combating the stomach pathogen. Lact. reuteri DSM17648 might prove useful as an adhesion blocker in antibiotic-free H. pylori therapies.

Publication types

  • Randomized Controlled Trial
  • Twin Study

MeSH terms

  • Adolescent
  • Bacterial Load*
  • Campylobacter jejuni / pathogenicity
  • Cross-Over Studies
  • Gastrointestinal Microbiome
  • Helicobacter Infections / therapy*
  • Helicobacter pylori / pathogenicity*
  • Humans
  • Lactobacillus reuteri / physiology*
  • Linear Models
  • Pilot Projects
  • Probiotics / administration & dosage
  • Single-Blind Method
  • Stomach / microbiology